Inmune Bio (INMB) Change in Accured Expenses (2018 - 2026)

Inmune Bio has reported Change in Accured Expenses for 9 years, with the latest figure at -$3.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 557.97% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (up 13.07% YoY) and the FY2025 annual result came in at $1.9 million, up 236.2% from the prior year.
• Change in Accured Expenses eased to -$3.0 million in Q1 2026 per INMB's latest filing, from $893000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.1 million in Q3 2023 and troughed at -$4.1 million in Q4 2024.
• A 5-year average of -$94235.3 and a median of $88000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 7013.33% in 2022, then surged 4041.67% in 2025.
• Over 5 years, Change in Accured Expenses stood at $1.2 million in 2022, then sank by 166.5% to -$804000.0 in 2023, then slumped by 403.86% to -$4.1 million in 2024, then surged by 122.04% to $893000.0 in 2025, then plunged by 437.96% to -$3.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.0 million, $893000.0, and -$170000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.